• 1. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 2. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 3. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 4. Exciting clusters, what does off-resonance actually mean??
  Goonay Yousefalizadeh,Shideh Ahmadi,Nicholas J. Mosey,Kevin G. Stamplecoskie Nanoscale, 2021,13, 242-252
• 5. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583

5-Iodo-6-methyl-7H-pyrrolo[2,3-d]pyrimidine (CAS 1638763-71-9): A Versatile Heterocyclic Compound for Pharmaceutical Research

5-Iodo-6-methyl-7H-pyrrolo[2,3-d]pyrimidine (CAS 1638763-71-9) is a highly specialized heterocyclic compound that has gained significant attention in pharmaceutical and medicinal chemistry research. This iodinated pyrrolopyrimidine derivative serves as a crucial building block for the development of novel drug candidates, particularly in oncology and antiviral therapies. Its unique molecular structure combines the pyrrolo[2,3-d]pyrimidine core with strategic substitutions that enhance its biological activity and synthetic utility.

The growing interest in 5-iodo-6-methyl-7H-pyrrolo[2,3-d]pyrimidine synthesis reflects the pharmaceutical industry's demand for targeted small molecules. Researchers frequently search for "pyrrolopyrimidine derivatives in drug discovery" and "iodinated heterocycles applications," highlighting the relevance of this compound in current medicinal chemistry trends. The presence of both iodine and methyl groups on the pyrrolo[2,3-d]pyrimidine scaffold makes it particularly valuable for structure-activity relationship (SAR) studies and molecular diversification.

From a chemical perspective, 5-iodo-6-methyl-7H-pyrrolo[2,3-d]pyrimidine demonstrates remarkable stability and solubility characteristics that make it suitable for various synthetic transformations. The iodine atom at position 5 serves as an excellent handle for cross-coupling reactions, enabling the construction of more complex molecular architectures. This property aligns with current research trends in "C-H functionalization of heterocycles" and "transition metal-catalyzed reactions," which are among the most searched topics in synthetic chemistry today.

The pharmaceutical applications of 5-iodo-6-methyl-7H-pyrrolo[2,3-d]pyrimidine are particularly noteworthy. As a pyrrolopyrimidine-based kinase inhibitor precursor, this compound has shown potential in addressing some of the most challenging medical conditions. Recent literature searches reveal growing interest in "pyrrolopyrimidines in cancer treatment" and "small molecule kinase inhibitors development," areas where this compound has demonstrated significant promise. The methyl group at position 6 often contributes to enhanced binding affinity and metabolic stability in drug candidates.

Market analysis indicates increasing demand for high-purity 5-iodo-6-methyl-7H-pyrrolo[2,3-d]pyrimidine from contract research organizations and pharmaceutical companies. The compound's CAS number (1638763-71-9) serves as a unique identifier in chemical databases and procurement systems, with many researchers specifically searching for "CAS 1638763-71-9 suppliers" or "pyrrolopyrimidine building blocks for drug discovery." This reflects the compound's established position in the medicinal chemistry toolbox.

Synthetic methodologies for 5-iodo-6-methyl-7H-pyrrolo[2,3-d]pyrimidine continue to evolve, with recent advances focusing on greener approaches and improved yields. Current research trends highlighted in "sustainable heterocycle synthesis" searches emphasize the importance of developing efficient routes to such valuable intermediates. The compound's molecular weight of 259.07 g/mol and well-defined physicochemical properties make it particularly amenable to modern synthetic techniques.

Quality control aspects of 5-iodo-6-methyl-7H-pyrrolo[2,3-d]pyrimidine are crucial for its research applications. Analytical techniques such as HPLC, NMR, and mass spectrometry are routinely employed to verify the compound's purity and identity. These quality assurance measures respond to the pharmaceutical industry's stringent requirements and address common search queries like "characterization of pyrrolopyrimidine derivatives" and "analytical methods for heterocyclic compounds."

The future outlook for 5-iodo-6-methyl-7H-pyrrolo[2,3-d]pyrimidine appears promising, with ongoing research exploring its potential in new therapeutic areas. As evidenced by increasing searches for "next-generation pyrrolopyrimidine drugs" and "targeted therapy development," this compound is likely to remain relevant in drug discovery pipelines. Its versatility as a synthetic intermediate positions it well for continued use in both academic and industrial settings.

Storage and handling recommendations for 5-iodo-6-methyl-7H-pyrrolo[2,3-d]pyrimidine typically involve protection from light and moisture, with stable performance at room temperature under inert atmosphere. These practical considerations address common laboratory questions about "stability of iodinated heterocycles" and "handling sensitive research chemicals," ensuring researchers can work with the compound effectively and safely.

In conclusion, 5-iodo-6-methyl-7H-pyrrolo[2,3-d]pyrimidine (CAS 1638763-71-9) represents a valuable tool in modern medicinal chemistry, combining synthetic versatility with biological relevance. Its applications span from kinase inhibitor development to broader pharmaceutical research, responding to current scientific trends and industry needs. As research continues to uncover new potential for pyrrolopyrimidine-based compounds, this particular derivative is poised to maintain its importance in the development of innovative therapeutic agents.

• 1256964-50-7(3-Iodo-2-methyl-1H-pyrrolo[2,3-b]pyridine)
• 1000340-29-3(3-Iodo-6-methyl-1H-pyrrolo[2,3-b]pyridine)
• 1229936-44-0(4-chloro-5-iodo-6-methyl-7H-pyrrolo[2,3-d]pyrimidine)
• 1638771-63-7(5-iodo-6-methyl-1H-pyrrolo[2,3-b]pyridine)
• 1638771-62-6(5-iodo-2-methyl-1H-pyrrolo[2,3-b]pyridine)
• 1303426-83-6(7H-Pyrrolo[2,3-d]pyrimidine, 5-iodo-4-methyl-)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)